Literature DB >> 26645808

Residue-based design of small molecule inhibitor for H1N1, H5N1 and H7N1 mutants.

Weng Ieong Tou1, Kun-Lung Chang2, Tung-Ti Chang3,4, Cheng-Chun Lee1,5, Calvin Yu-Chian Chen6,7,8,9.   

Abstract

Point mutations H274Y and N294S can lead to resistance of influenza virus strains to some drug molecules. Recently, a large number of experiments has focused on the many frameworks and catalytic residues thought to prevent the efficacy of anti-flu drugs. In the past, most research has considered the role of drugs in rigid proteins rather than in flexible proteins. In this study, we used molecular dynamics simulation (MD) combined with structure- and ligand-based drug design (SBDD and LBDD) methods to study dynamic interaction and protein dynamics correlation statistics between compounds and both the framework and catalytic residues in influenza virus N1 strains. Drug candidates were screened using the IC50 of the docking result predicted by support vector machine, multiple linear regression, and genetic function approximation (P < 0.001). As shown by MD, saussureamine C and diiodotyrosine have a protein dynamics correlation similar to that of sialic acid, and both can participate in hydrogen bond formation with loop, framework, and catalytic residues. Our in silico findings suggest that saussureamine C can inhibit H274Y and N294S mutants, and that diiodotyrosine can also inhibit N294S mutants. Therefore, the drugs saussureamine C and diiodotyrosine have the potential to produce inhibitory effects on wild-type influenza virus and some N1 mutants.

Entities:  

Keywords:  Drug discovery; H1N1; H5N1; H7N1; Traditional Chinese medicine

Mesh:

Substances:

Year:  2015        PMID: 26645808     DOI: 10.1007/s00894-015-2875-y

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  31 in total

1.  Structure validation by Calpha geometry: phi,psi and Cbeta deviation.

Authors:  Simon C Lovell; Ian W Davis; W Bryan Arendall; Paul I W de Bakker; J Michael Word; Michael G Prisant; Jane S Richardson; David C Richardson
Journal:  Proteins       Date:  2003-02-15

2.  Oseltamivir resistance--disabling our influenza defenses.

Authors:  Anne Moscona
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  Oseltamivir becomes plentiful--but still not cheap.

Authors:  Martin Enserink
Journal:  Science       Date:  2006-04-21       Impact factor: 47.728

4.  iScreen: world's first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan.

Authors:  Tsung-Ying Tsai; Kai-Wei Chang; Calvin Yu-Chian Chen
Journal:  J Comput Aided Mol Des       Date:  2011-06-07       Impact factor: 3.686

5.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit.

Authors:  Sander Pronk; Szilárd Páll; Roland Schulz; Per Larsson; Pär Bjelkmar; Rossen Apostolov; Michael R Shirts; Jeremy C Smith; Peter M Kasson; David van der Spoel; Berk Hess; Erik Lindahl
Journal:  Bioinformatics       Date:  2013-02-13       Impact factor: 6.937

6.  Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.

Authors:  Jesse D Bloom; Lizhi Ian Gong; David Baltimore
Journal:  Science       Date:  2010-06-04       Impact factor: 47.728

7.  Traditional Chinese medicine as dual guardians against hypertension and cancer?

Authors:  Weng Ieong Tou; Calvin Yu-Chian Chen
Journal:  J Biomol Struct Dyn       Date:  2012-06-12

8.  Molecular dynamics simulations suggest that electrostatic funnel directs binding of Tamiflu to influenza N1 neuraminidases.

Authors:  Ly Le; Eric H Lee; David J Hardy; Thanh N Truong; Klaus Schulten
Journal:  PLoS Comput Biol       Date:  2010-09-23       Impact factor: 4.475

9.  Effects of hexose starvation and the role of sialic acid in influenza virus release.

Authors:  J A Griffin; S Basak; R W Compans
Journal:  Virology       Date:  1983-03       Impact factor: 3.616

10.  In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.

Authors:  Weng Ieong Tou; Calvin Yu-Chian Chen
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.